Surgical Science Sweden AB (SUS) — Capital Reinvestment Ratio

Latest as of December 2025: 0.09x

Surgical Science Sweden AB (SUS) has a Capital Reinvestment Ratio of 0.09x as of December 2025, meaning it reinvests 0% of its operating cash flow (Skr72.89 Million) in capital expenditures (Skr6.24 Million). See how leveraged is Surgical Science Sweden AB's balance sheet to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.09x
Capex / Operating Cash Flow

Operating Cash Flow

Skr72.89 Million
SEK

Capital Expenditures

Skr6.24 Million
SEK

Data as of

Dec 2025
Most recent filing

Surgical Science Sweden AB Capital Reinvestment Ratio (2015–2025)

This chart tracks Surgical Science Sweden AB's Capital Reinvestment Ratio across 11 annual periods. Check how aggressively does Surgical Science Sweden AB reinvest cash to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Surgical Science Sweden AB (2015–2025)

Year-by-year Capital Reinvestment Ratio for Surgical Science Sweden AB from 2015 to 2025. For live market cap and broader valuation context, see Surgical Science Sweden AB market capitalisation.

Year Reinvestment Ratio Operating CF (SEK) Capital Expenditures YoY Change
2025 0.15x Skr79.80 Million Skr11.68 Million ▼ -57.7%
2024 0.35x Skr137.22 Million Skr47.53 Million ▲ +87.0%
2023 0.19x Skr238.29 Million Skr44.13 Million ▼ -30.6%
2022 0.27x Skr129.49 Million Skr34.55 Million ▼ -27.5%
2021 0.37x Skr39.08 Million Skr14.38 Million ▼ -1.7%
2020 0.37x Skr23.23 Million Skr8.69 Million ▲ +131.8%
2019 0.16x Skr55.20 Million Skr8.91 Million ▼ -87.1%
2018 1.26x Skr6.88 Million Skr8.64 Million ▼ -17.7%
2017 1.53x Skr7.94 Million Skr12.12 Million ▲ +74.8%
2016 0.87x Skr13.40 Million Skr11.70 Million ▼ -21.1%
2015 1.11x Skr7.50 Million Skr8.30 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow